(NASDAQ: BBIO) Bridgebio Pharma's forecast annual revenue growth rate of 68.69% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.63%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.32%.
Bridgebio Pharma's revenue in 2026 is $502,076,000.On average, 24 Wall Street analysts forecast BBIO's revenue for 2026 to be $183,146,131,491, with the lowest BBIO revenue forecast at $149,479,905,313, and the highest BBIO revenue forecast at $213,249,158,100. On average, 23 Wall Street analysts forecast BBIO's revenue for 2027 to be $318,904,422,795, with the lowest BBIO revenue forecast at $209,565,763,551, and the highest BBIO revenue forecast at $463,526,124,561.
In 2028, BBIO is forecast to generate $470,117,462,175 in revenue, with the lowest revenue forecast at $387,919,604,871 and the highest revenue forecast at $581,976,338,742.